Nationwide digital healthcare platform soon

timesofindia | May 06, 2016

NEW DELHI: Moving towards digitisation of healthcare, the health ministry has worked out a detailed e-health project under digital India initiative of the government. The project would include hospital information system, electronic health record facilitated with health information exchange, online delivery of services, citizen portal, online monitoring systems for services and others, health minister JP Nadda informed the Lok Sabha on Friday.

Spotlight

Growing awareness of celiac disease and gluten intolerance has driven the retail sales of Canada's gluten free products and market is expected to reach USD600 Mn by 2014. Despite market competition introduction of new products and rising marketing efforts are going to drive the gluten free market in coming years.

Spotlight

Growing awareness of celiac disease and gluten intolerance has driven the retail sales of Canada's gluten free products and market is expected to reach USD600 Mn by 2014. Despite market competition introduction of new products and rising marketing efforts are going to drive the gluten free market in coming years.

Related News

HEALTH TECHNOLOGY

GE Healthcare Announces $80 Million Investment To Expand Contrast Media Production Capacity

GE Healthcare | November 18, 2022

GE Healthcare’s Pharmaceutical Diagnostics business announced an $80 million investment to increase manufacturing capacity by 30 percent at its Active Pharmaceutical Ingredients site in Lindesnes, Norway. The investmentwhich is creating around 100 new jobs – is part of GE Healthcare’s broader commitment to address significant future global demand for iodinated contrast media, used in Xray and Computed Tomography procedures around the world to enhance visualization of organs, blood vessels and tissues across disease pathways. Iohexol and iodixanol API are used in over 100 million patient doses of GE iodinated contrast media annually, equivalent to three patient procedures every second. This new investment, coupled with the recent opening of a new production line at GE Healthcare’s Cork, Ireland, fill and finish facility, aims to enable the production of 30 million more patient doses per year by 2025. “We expect global demand for iodinated contrast media to double in the next 10 years, driven by global prevalence of chronic disorders and significant growth in CT procedures. This investment in capacity expansion at our Lindesnes facility is another example of how we, as an industry leader, are addressing this growing demand to meet the needs of our customers and their patients across the globe.” President & CEO of GE Healthcare Pharmaceutical Diagnostics, Kevin O’Neill The 100-acre Lindesnes site in southern Norway, has been operating since 1974 and employs 450 people, who use multiple chemical pharmaceutical processes to convert iodine into finished API. Recently, GE Healthcare announced a multi-year agreement with SQM, a Chile-based mining company, to secure increasing supply of iodine, the key ingredient in iodinated contrast media. GE Healthcare is the world’s leading supplier of contrast media, used to support patient imaging procedures in 130+ countries globally. All stages of its contrast media manufacturing, from development of Active Pharmaceutical Ingredient (API) to finished product, are managed entirely by GE Healthcare, adhering to current Good Manufacturing Practices. With over 4000 employees globally and seven manufacturing sites, the Pharmaceutical Diagnostics business also develops and supplies radiopharmaceuticals used to support diagnosis, monitoring and treatment selection across Neurology, Cardiology and Oncology clinical pathways. About GE Healthcare GE Healthcare is the $17.7 billion healthcare business of GE. As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Read More

HEALTH TECHNOLOGY

Veranex Expands European MedTech Capabilities With Acquisition of Medidee

Veranex and Medidee Services | September 21, 2022

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced that it has acquired Medidee, a top MedTech consultancy company headquartered in Lausanne, Switzerland. As a trusted European regulatory and quality service consultancy joining Veranex, Medidee expands and strengthens regulatory affairs, clinical development, and quality assurance services and capabilities for MedTech companies across Europe and the world. This improved ability to navigate the European Union’s Medical Device and In Vitro Diagnostic Device Regulations challenges supports truly full-service MedTech product development and commercialization. “Our acquisition of Medidee significantly expands our European footprint while also materially expanding the scale and scope of the clinical studies we can manage. The combined organization offers offices and expertise across Europe, the U.S., and Asia, augmenting our ability to help MedTech innovators achieve FDA and CE Mark approvals and uninterrupted market access for new as well as proven medical technologies that advance patient care.” Veranex CEO David Dockhorn With Medidee’s 11 locations across Europe, India, and Asia-Pacific, and Veranex’s 13 locations across the U.S., Europe, and China, the company now has unprecedented reach to serve clients with a full spectrum of integrated concept-to-commercialization services — design, engineering, regulatory, quality, preclinical research, clinical development, clinical operations, commercial strategy, and market access services — all under one umbrella. Medidee is one of the Top 3 medical device consultancy service providers in Europe uniquely positioned as a leader in future key areas such as digital health, machine learning, and cybersecurity. The company also brings expertise in clinical research exclusively focused on medical devices and in vitro diagnostics. “Medidee has a proven track record serving regulatory, clinical, and quality needs for companies of all sizes, with consulting expertise and clinical trial support in increasingly diverse therapeutic areas and technology categories across multiple geographies,” shared Medidee co-founders Kim Rochat, Philippe Etter, and Michael Maier. “With these services, coupled with the global infrastructure of Veranex, we expand expertise and resources for the benefit of our clients as well as for all EU innovative manufacturers wishing to access rapidly and efficiently the U.S. market and beyond. We look forward to providing these additional strengths and capabilities,” added the co-founders who take on new roles in the combined organization. About Veranex Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its comprehensive solutions unify and streamline the entire development process. Veranex is backed by Summit Partners, Accelmed, and Lauxera Capital Partners. About Medidee Services With sites in Switzerland, Germany, Denmark, Belgium, Spain, USA, and APAC, Medidee is a global services supplier serving companies ranging from academic startups to majors. Medidee was established by three partners, all experts in the field of medical devices. With 50 experts in all fields necessary to ensure compliance with the most stringent requirements, Medidee provides the necessary competencies to ensure and demonstrate compliance with all key medical device regulations. Medidee expends regularly to provide the best resources and competencies and supports more than 350 manufactures all over the world.

Read More

HEALTH TECHNOLOGY

Radius XR a new fashion-forward wearable technology brand brings together multimodal diagnostics practice management and patient engagement

Radius XR | October 03, 2022

IrisVision co-founder and CEO Ammad Khan today introduced a new company, Radius XR, to coincide with the opening of the American Academy of Ophthalmology 2022 meeting in Chicago. Radius XR builds on the therapeutic legacy of IrisVision by introducing diagnostic capability to the proprietary VR/AR assistive device. After the CES Award-winning 2017 launch of IrisVision, which has helped thousands of legally blind individuals see again, the company sought to leverage its core technology to benefit the eyecare industry by creating a patient-guided exam process that makes it easier and more affordable to diagnose a range of vision problems that are pervasive in the U.S. More than 32 million Americans aged 18+ are affected by vision loss, according to the IPUMS National Health Interview Survey1. Using a single Radius XR headset, patients can self-perform a range of vision tests that are clinically equivalent to gold standard exams. The exams currently performed with the Radius XR testing platform are Visual Field, Visual Acuity, Contrast Sensitivity, Amsler Grid, and Color Scheme. Development is ongoing. The shift to patient-guided testing enhances eyecare practice workflow and enables a single technician to administer several test sessions concurrently, doubling patient capacity. The fashion-forward design of Radius XR is a significant leap forward in wearable devices, with the look and feel of a pair of fashionable sunglasses. Radius XR is the industry’s lightest wearable device, weighing just under 6 oz., and features all-day battery life. The small, lightweight design overcomes the challenges of expensive and bulky legacy devices that force patients to sit in uncomfortable positions for testing. Exams can be conducted beyond exam lanes, allowing a patient’s exam in nontraditional spaces like waiting rooms, remote offices, and lobbies. With Radius XR, opportunities for greater accessibility and care are boundless. A breakthrough feature of the Radius XR platform is the immersive educational media library that can be tailored to each patient. This content is configured by each practice to display at an appropriate time during the exam experience automatically, eliminating the repetitive, time-consuming task of providing patients with educational information about their vision challenges while ensuring relevant information is consistently presented. The platform includes a Business Suite of management tools that streamline patient check-in, enable staff to customize the experience for multiple patients, and make it easier for eyecare professionals to manage business aspects critical to their practice's ongoing success. Trefethen named Radius XR CMO The launch of Radius XR is guided by John Trefethen, who joins the company as Chief Marketing Officer. Trefethen previously served in leadership roles at several medical device companies, including industry giants Zeiss Medical Technology and Topcon Healthcare. “Early diagnosis is the key to treating many conditions that can lead to vision loss. We believe a testing platform that combines a comfortable size with an engaging, immersive experience makes patients more likely to seek testing — and to be re-tested more frequently. Diagnosing conditions earlier and regularly tracking disease progression gives eyecare professionals an immense advantage in caring for their patients’ vision. Trefethen About Radius XR – RadiusXR The Radius XR platform is a portable vision diagnostic and patient engagement system that combines medical-grade diagnostics, business management, and patient education tools in a single wearable AR/VR device. The RadiusExam® proprietary algorithm provides diagnostic testing results equivalent to current exam gold standards, with the clinical science validated by Deming regression. As the algorithm presents stimuli to patients, Radius Adaptive® responds to maximize the algorithm's speed. The total hardware and software system helps medical professionals diagnose patients with accuracy, grow their eyecare practices, enhance patient engagement, and reduce staff workload by enabling patients to perform self-guided vision exams with minimal supervision. Radius XR builds on the therapeutic legacy of IrisVision, the first clinically validated wearable low vision solution. IrisVision was backed by a research grant from the National Eye Institute and developed in collaboration with researchers from top ophthalmology centers at Johns Hopkins University, Stanford University, and UPMC Pittsburg.

Read More